Actionable news
0
All posts from Actionable news
Actionable news in PETX: Aratana Therapeutics, Inc.,

Prospectus [Rule 424(b)(5)]

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-197414

PROSPECTUS SUPPLEMENT

$52,000,000

Common Stock

We have entered into a sales agreement with Barclays Capital Inc., or Barclays, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $52 million from time to time through Barclays as our sales agent.

Our common stock is listed on The NASDAQ Global Market under the symbol “PETX.” On October 14 , 2015, the last reported sale price of our common stock on The NASDAQ Global Market was $ 7.18 per share.

Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through The NASDAQ Global Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. Barclays is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Barclays and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The compensation to Barclays for sales of common stock sold pursuant to the sales agreement will be an amount equal to 2.75% of the gross proceeds of any shares of common stock sold under the sales agreement. See “Plan of Distribution” for additional information regarding the compensation to be paid to Barclays. In connection with the sale of the common stock on our behalf, Barclays may be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Barclays will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Barclays with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.

Investing in our common stock involves a high degree of risk. Please read “RISK FACTORS” beginning on page S-3 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement concerning factors you should consider before investing in our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Barclays

Prospectus Supplement dated October 16 , 2015.

TABLE OF CONTENTS

PROSPECTUS SUPPLEMENT

Page

ACCOMPANYING PROSPECTUS

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is in two parts. The first part is the prospectus supplement, including the documents incorporated by...


More